Text Size

VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

This study is currently recruiting participants.
Verified July 2012 by Institute of Vision, Brasil
Sponsor:
Information provided by (Responsible Party):
Institute of Vision, Brasil
ClinicalTrials.gov Identifier:
NCT01655589
First received: July 31, 2012
Last updated: NA
Last verified: July 2012
History: No changes posted
  Purpose

The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.


Condition
Macular Degeneration

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: VEGF Gene Polymorphism and Response to Intravitreal Anti-VEGF Agents in Neovascular Age-related Macular Degeneration

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Institute of Vision, Brasil:

Estimated Enrollment: 74
Study Start Date: January 2008
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Eye clinic in Belo Horizonte, Brazil

Criteria

Inclusion Criteria:

  • Diagnosis of neovascular age-related macular degeneration
  • Visual acuity better than 20/400
  • Loading dose with three intravitreal injections of anti-VEGF agents, administred one per month over three months
  • Follow-up period of at least six months

Exclusion Criteria:

  • Choroidal neovascularization secondary to any other cause than age-related macular degeneration
  • Eyes with polypoidal choroidal vasculopathy
  • Eyes previously submitted to posterior vitrectomy
  • Other diseases that could affect visual acuity
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01655589

Locations
Brazil
Institute of Vision Recruiting
Belo Horizonte, MG, Brazil, 30150270
Contact: Andre B Ferreira     55 31 32743355     andre@ivisao.com    
Sponsors and Collaborators
Institute of Vision, Brasil
  More Information

No publications provided

Responsible Party: Institute of Vision, Brasil
ClinicalTrials.gov Identifier: NCT01655589     History of Changes
Other Study ID Numbers: IV-01
Study First Received: July 31, 2012
Last Updated: July 31, 2012
Health Authority: Brazil: National Committee of Ethics in Research

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases

ClinicalTrials.gov processed this record on May 22, 2013